Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Authors
Califano, RaffaeleGriffiths, Richard W
Lorigan, Paul C
Ashcroft, Linda
Taylor, Paul
Burt, Paul A
Lee, Lip W
Chittalia, Abbas
Harris, Maggie A
Faivre-Finn, Corinne
Thatcher, Nick
Blackhall, Fiona H
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. raffaele.califano@christie.nhs.ukIssue Date
2011-09
Metadata
Show full item recordAbstract
The role of chemotherapy for advanced NSCLC patients and ECOG PS2 remains controversial. We evaluated 4 doses of 3-weekly docetaxel to identify a less toxic, clinically effective dose.Citation
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. 2011, 73 (3):338-44 Lung CancerJournal
Lung CancerDOI
10.1016/j.lungcan.2011.01.001PubMed ID
21296449Type
ArticleLanguage
enISSN
1872-8332ae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2011.01.001
Scopus Count
Related articles
- First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
- Authors: Gebbia V, Lorusso V, Galetta D, Caruso M M, Palomba G, Riccardi F, Borsellino N, Carrozza F, Leo S, Ferraù F, Cinieri S, Mancuso G, Mancarella S, Colucci G
- Issue date: 2010 Aug
- Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
- Authors: Novello S, Falcone A, Crinò L, Rinaldi M, Nardi M, De Marinis F, Tonato M, Tibaldi C, Tinazzi A, Russo F, Grassivaro N, Scagliotti GV
- Issue date: 2009 Dec
- A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
- Authors: Kim HJ, Kim TG, Lee HJ, Kim JH, Lim BH, Seo JW, Kang EM, Lee BU, Ahn YM, Roh YH, Nam SH, Kim BS
- Issue date: 2010 May
- A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
- Authors: Grossi F, de Marinis F, Gebbia V, Riccardi F, Caffo O, Gamucci T, Ferraù F, Nardi M, Moscetti L, Boni L, Dondi D, Galligioni E
- Issue date: 2012 Feb
- A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
- Authors: Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, Mavroudis D, Georgoulias V
- Issue date: 2011 Aug